X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
humans (15) 15
immunology (14) 14
oncology (11) 11
cancer (10) 10
melanoma (10) 10
immunotherapy (9) 9
female (8) 8
middle aged (8) 8
aged (7) 7
lymphocytes t (7) 7
male (7) 7
adult (6) 6
care and treatment (6) 6
clinical trials (6) 6
ipilimumab (6) 6
lymphocytes (6) 6
metastases (6) 6
t cells (6) 6
antibodies (5) 5
antigens (5) 5
metastasis (5) 5
pembrolizumab (5) 5
survival (5) 5
antigen-presenting cells (4) 4
autoimmunity (4) 4
dendritic cells (4) 4
drug therapy (4) 4
enzyme-linked immunosorbent assay (4) 4
generation (4) 4
immune response (4) 4
immune system (4) 4
medicine (4) 4
medicine, research & experimental (4) 4
melanoma - drug therapy (4) 4
peptides (4) 4
responses (4) 4
antigen (3) 3
antineoplastic agents - therapeutic use (3) 3
autoimmune diseases (3) 3
breast cancer (3) 3
cancer therapies (3) 3
cancer vaccines - therapeutic use (3) 3
cd8 antigen (3) 3
cd8-positive t-lymphocytes - immunology (3) 3
cd8-positive t-lymphocytes - metabolism (3) 3
cell activation (3) 3
cell line, tumor (3) 3
cells, cultured (3) 3
chemical and pharmacologic phenomena (3) 3
chemotherapy (3) 3
ctla-4 (3) 3
cytotoxicity (3) 3
dendritic cells - immunology (3) 3
enzymes (3) 3
epitopes (3) 3
histocompatibility antigen hla (3) 3
identification (3) 3
inflammation (3) 3
interleukin 2 (3) 3
interleukin-2 - therapeutic use (3) 3
major histocompatibility complex (3) 3
malignant melanoma (3) 3
neoplasm metastasis (3) 3
nivolumab (3) 3
patients (3) 3
therapy (3) 3
treatment outcome (3) 3
vaccination (3) 3
vaccines (3) 3
young adult (3) 3
abridged index medicus (2) 2
activation (2) 2
adolescent (2) 2
adoptive transfer (2) 2
amino acid sequence (2) 2
analysis (2) 2
anti-cd8 antibodies (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antigen processing and recognition (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
apoptosis (2) 2
biomarkers (2) 2
blocking antibodies (2) 2
cancer immunotherapy (2) 2
cancer patients (2) 2
cancer vaccines (2) 2
cancer vaccines - immunology (2) 2
cancer-patients (2) 2
carcinoma (2) 2
carcinoma, renal cell - therapy (2) 2
cd4 (2) 2
cd8 coreceptor (2) 2
checkpoint inhibitors (2) 2
confidence intervals (2) 2
ctla-4 antigen - antagonists & inhibitors (2) 2
data processing (2) 2
dendritic cell vaccination (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
by Lundqvist, Andreas and van Hoef, Vincent and Zhang, Xiaonan and Wennerberg, Erik and Lorent, Julie and Witt, Kristina and Sanz, Laia Masvidal and Liang, Shuo and Murray, Shannon and Larsson, Ola and Kiessling, Rolf and Mao, Yumeng and Sidhom, John-William and Bessell, Catherine A and Havel, Jonathan and Schneck, Jonathan and Chan, Timothy A and Sachsenmeier, Eliot and Woods, David and Berglund, Anders and Ramakrishnan, Rupal and Sodre, Andressa and Weber, Jeffrey and Zappasodi, Roberta and Li, Yanyun and Qi, Jingjing and Wong, Philip and Sirard, Cynthia and Postow, Michael and Newman, Walter and Koon, Henry and Velcheti, Vamsidhar and Callahan, Margaret K and Wolchok, Jedd D and Merghoub, Taha and Lum, Lawrence G and Choi, Minsig and Thakur, Archana and Deol, Abhinav and Dyson, Gregory and Shields, Anthony and Haymaker, Cara and Uemura, Marc and Murthy, Ravi and James, Marihella and Wang, Daqing and Brevard, Julie and Monaghan, Catherine and Swann, Suzanne and Geib, James and Cornfeld, Mark and Chunduru, Srinivas and Agrawal, Sudhir and Yee, Cassian and Wargo, Jennifer and Patel, Sapna P and Amaria, Rodabe and Tawbi, Hussein and Glitza, Isabella and Woodman, Scott and Hwu, Wen-Jen and Davies, Michael A and Hwu, Patrick and Overwijk, Willem W and Bernatchez, Chantale and Diab, Adi and Massarelli, Erminia and Segal, Neil H and Ribrag, Vincent and Melero, Ignacio and Gangadhar, Tara C and Urba, Walter and Schadendorf, Dirk and Ferris, Robert L and Houot, Roch and Morschhauser, Franck and Logan, Theodore and Luke, Jason J and Sharfman, William and Barlesi, Fabrice and Ott, Patrick A and Mansi, Laura and Kummar, Shivaani and Salles, Gilles and Carpio, Cecilia and Meier, Roland and Krishnan, Suba and McDonald, Dan and Maurer, Matthew and Gu, Xuemin and Neely, Jaclyn and Suryawanshi, Satyendra and Levy, Ronald and Khushalani, Nikhil and Wu, Jennifer and Zhang, Jinyu and Basher, Fahmin and Rubinstein, Mark and Bucsek, Mark and Qiao, Guanxi and ...
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2016, Volume 4, Issue S1
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 08/2012, Volume 10, Issue 1, pp. 169 - 169
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2012, Volume 7, Issue 4, p. e34568
Background: The enzyme indoleamine 2,3-dioxygenase (IDO) contributes to immune tolerance in a variety of settings. In cancer IDO is expressed within the tumor... 
INHIBITION | DENDRITIC CELLS | IDO | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | IN-VIVO | GENERATION | SUPPRESSION | CANCER | TUMOR-IMMUNITY | TH17 CELLS | Indoleamine-Pyrrole 2,3,-Dioxygenase - metabolism | Tumor Necrosis Factor-alpha - metabolism | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - therapeutic use | Interferon-gamma - metabolism | Epitopes - immunology | Peptides - metabolism | T-Lymphocytes, Helper-Inducer - immunology | CD8-Positive T-Lymphocytes - metabolism | Interleukin-10 - metabolism | Female | Histocompatibility Antigens Class II - metabolism | T-Lymphocytes, Helper-Inducer - metabolism | HLA-A2 Antigen - immunology | Interleukin-17 - metabolism | Histocompatibility Antigens Class II - immunology | Melanoma - drug therapy | Aged | HLA-A2 Antigen - metabolism | CD8-Positive T-Lymphocytes - immunology | Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors | Peptides - therapeutic use | Peptides | CD8 antigen | Blocking antibodies | Antibodies | Cytotoxicity | Oncology | Tryptophan 2,3-dioxygenase | Lymphocytes T | Infections | Vaccines | Lymph nodes | Cell activation | Immunology | Lymphocytes | Immunotherapy | Enzyme-linked immunosorbent assay | Antigens | Enzymes | Cytomegalovirus | Hematology | Dendritic cells | Immunoregulation | Melanoma | Inflammation | T cell receptors | Breast cancer | Epitopes | Tumor necrosis factor-α | Patients | Immunological tolerance | Interleukin 17 | CD4 antigen | Drainage | Antigen-presenting cells | Antigen (tumor-associated) | γ-Interferon | Interleukin 10 | Ligands | Interferon | Histocompatibility antigen HLA | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2009, Volume 4, Issue 9, p. e6910
Journal Article
OncoImmunology, ISSN 2162-4011, 01/2015, Volume 4, Issue 1, p. 968480
Tryptophan-2,3-dioxygenase (TDO) physiologically regulates systemic tryptophan levels in the liver. However, numerous studies have linked cancer with... 
T cells | Th17 | Tregs | immune regulation | TDO | MECHANISM | INDOLEAMINE 2,3-DIOXYGENASE | KINASE | IMMUNOLOGY | IDENTIFICATION | ESCAPE | RESPONSES | ONCOLOGY | INFLAMMATION | DIOXYGENASE | TUMORAL IMMUNE RESISTANCE | TH17 CELLS
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 10/2012, Volume 61, Issue 10, pp. 1791 - 1804
Dendritic cells (DC) are the most potent antigen presenting cells and have proven effective in stimulation of specific immune responses in vivo. Competing... 
Immunology | Medicine & Public Health | Immunotherapy | Malignant melanoma | Oncology | Cancer Research | Dendritic cell vaccination | Metronomic cyclophosphamide | IMMUNE-RESPONSE | CYCLOOXYGENASE-2 | LOW-DOSE CYCLOPHOSPHAMIDE | MALIGNANT-MELANOMA | IMMUNOLOGY | TUMOR-IMMUNITY | CHEMOTHERAPY | COX-2 EXPRESSION | CANCER-PATIENTS | ONCOLOGY | REGULATORY T-CELLS | SUPPRESSOR-CELLS | Bone Neoplasms - mortality | Pyrazoles - therapeutic use | Skin Neoplasms - drug therapy | Administration, Metronomic | Dendritic Cells - immunology | Humans | Middle Aged | Interleukin-2 - therapeutic use | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Young Adult | Cancer Vaccines - therapeutic use | Interleukin-2 - immunology | Skin Neoplasms - mortality | Cyclooxygenase 2 Inhibitors - therapeutic use | Aged, 80 and over | Adult | Female | Bone Neoplasms - drug therapy | Skin Neoplasms - pathology | HLA-A2 Antigen - immunology | Skin Neoplasms - immunology | Treatment Outcome | Bone Neoplasms - immunology | Combined Modality Therapy | Celecoxib | Melanoma - secondary | Cancer Vaccines - immunology | T-Lymphocytes, Regulatory - drug effects | Sulfonamides - therapeutic use | Melanoma - immunology | Melanoma - drug therapy | Aged | Melanoma - mortality | survivin | Immune response | Dendritic cells | Immunoregulation | Vaccination | Melanoma | Clinical trials | Lymphocytes T | Vaccines | Survival | Metastases | Cyclophosphamide | Interleukin 2 | Antigen-presenting cells | gamma -Interferon | Histocompatibility antigen HLA | Cyclooxygenase-2 | telomerase reverse transcriptase | Enzyme-linked immunosorbent assay | Tumors
Journal Article